SIGA PHARMACEUTICALS INC
S-3, EX-5, 2000-08-14
PHARMACEUTICAL PREPARATIONS
Previous: SIGA PHARMACEUTICALS INC, S-3, 2000-08-14
Next: SIGA PHARMACEUTICALS INC, S-3, EX-23.2, 2000-08-14




                                August 14, 2000

Siga Technologies, Inc.
420 Lexington Avenue- Suite 620
New York, New York 10170

            Re:  Siga Technologies, Inc.
                 Registration Statement on Form S-3

      We have acted as counsel to Siga Technologies, Inc., a Delaware
corporation (the "Company"), in connection with the preparation and filing of a
Registration Statement on Form S-3 (the "Registration Statement") with the
Securities and Exchange Commission under the Securities Act of 1933, as amended
(the "Act"). The Registration Statement relates to the sale by certain selling
stockholders of the Company of up to 1,093,036 shares of the Company's Common
Stock (the "Shares"). This opinion is being furnished in accordance with the
requirements of item 16 of Form S-3 and Item 601(b)(5)(i) of Regulation S-K.

      We have reviewed the Company's charter documents and the corporate
proceedings taken by the Company in connection with the issuance of the Shares.
Based on such review, we are of the opinion that the Shares have been duly
authorized, and if, as and when sold in accordance with the Registration
Statement and the related prospectus (as amended and supplemented through the
date of sale) will be legally issued, fully paid and nonassessable.

      We consent to the filing of this opinion letter as Exhibit 5.1 to the
Registration Statement and to the reference to this firm under the caption
"Legal Matters" in the prospectus which is part of the Registration Statement.
In giving this consent, we do not thereby admit that we are within the category
of persons whose consent is required under Section 7 of the Act, the rules and
regulations of the Securities and Exchange Commission promulgated thereunder, or
Item 509 of Regulation S-K.

      This opinion letter is rendered as of the date first written above and we
disclaim any obligation to advise you of facts, circumstances, events or
developments which hereafter may be brought to our attention and which may
alter, affect or modify the opinion expressed herein. Our opinion is expressly
limited to the matters set forth above and we render no opinion, whether by
implication or otherwise, as to any other matters relating to the Company or the
Shares.

                                Very truly yours,


                                /s/ Camhy Karlinsky & Stein LLP



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission